Compare · AAPG vs NVO
AAPG vs NVO
Side-by-side comparison of Ascentage Pharma Group International (AAPG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AAPG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 126.5x AAPG ($1.71B).
- Over the past year, AAPG is down 54.0% and NVO is down 32.0% - NVO leads by 22.0 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 9 for AAPG).
- Company
- Ascentage Pharma Group International
- Novo Nordisk A/S
- Price
- $18.32-6.58%
- $48.78+1.22%
- Market cap
- $1.71B
- $215.95B
- 1M return
- +6.91%
- +2.89%
- 1Y return
- -53.96%
- -31.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 5
- 5
- Recent ratings
- 9
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AAPG
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form F-3ASR filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 3 filed by new insider Miyara Faical
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
- SEC Form 6-K filed by Ascentage Pharma Group International
- B. Riley Securities initiated coverage on Ascentage Pharma with a new price target
- SEC Form 6-K filed by Ascentage Pharma Group International
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S